Pds biotechnology post-asco conference call tomorrow, june 6, at 8 a.m. et

Florham park, n.j., june 05, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the company will be hosting a conference call and webcast tomorrow, june 6, 2023, to discuss the promising interim data from the versatile-002 (nct04260126) phase 2 clinical trial investigating pds0101 in combination with merck's anti-pd-1 therapy, keytruda® (pembrolizumab), presented at the 2023 american society for clinical oncology (asco) meeting.
PDSB Ratings Summary
PDSB Quant Ranking